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Whole-genome sequences for Stenotrophomonas maltophilia serial isolates from a bacteremic patient before and after develop-
ment of levofloxacin resistance were assembled de novo and differed by one single-nucleotide variant in smeT, a repressor for
multidrug efflux operon smeDEF. Along with sequenced isolates from five contemporaneous cases, they displayed considerable
diversity compared against all published complete genomes. Whole-genome sequencing and complete assembly can conclusively
identify resistance mechanisms emerging in S. maltophilia strains during clinical therapy.
Stenotrophomonas maltophilia is an aerobic, nonfermenting,and motile Gram-negative bacterium that is increasingly rec-
ognized as a cause of hospital-acquired infections, with crude
mortality rates of 14 to 69% in cases of bacteremia (1). Treatment
of S. maltophilia infections is challenging due to the pathogen’s
intrinsic resistance to many antibiotic classes via drug efflux
pumps, beta-lactamase production, and decreased membrane
permeability (1). Resistance phenotypes are known to change
during the course of treatment, which complicates interpretation
of automated drug susceptibility testing (DST) results (2). A mu-
tant strain of S. maltophilia with emerging resistance to tetracy-
cline, chloramphenicol, and quinolones was previously character-
ized following in vitro tetracycline selection (3, 4). However, little
is known about the genetic and molecular mechanisms underly-
ing acquired resistance in the clinical setting—particularly for
quinolones, as, in contrast to other Gram-negative organisms, the
quinolone-resistance determining region (QRDR) of topoisom-
erase genes is often unaltered (5). In this report, we describe the
first reported use of whole-genome sequencing (WGS) in serial
clinical isolates to definitively identify an acquired quinolone re-
sistance mutation in S. maltophilia.
WGS was performed for the initial and subsequent S. malto-
philia blood culture isolates from a patient for whom acquired
quinolone resistance was observed (patient 1) and five other pa-
tients (patients 2 to 6) selected from a 2-month period in 2013 at
The Mount Sinai Hospital. Patient 1 was a 56-year-old man re-
quiring urgent placement of an intrahepatic shunt for complica-
tions of a Whipple procedure, which was followed by several epi-
sodes of bacteremia that were treated with multiple courses of
antimicrobials, including levofloxacin. Two months later, another
bacteremia developed, and blood cultures intermittently grew S.
maltophilia despite antimicrobial therapy. Automated DST by
Vitek2 (bioMérieux, Marcy l’Etoile, France) showed that the first
S. maltophilia isolate acquired (ISMMS2) was susceptible to fluo-
roquinolones and trimethoprim-sulfamethoxazole (SXT). After
treatment with ciprofloxacin the bacteremia initially cleared, but
blood cultures 9 days later again grew S. maltophilia (isolated as
ISMMS2R), now resistant to fluoroquinolones while still suscep-
tible to SXT. Ciprofloxacin was stopped and intravenous SXT was
given; subsequent cultures did not grow S. maltophilia.
Standard culturing and susceptibility testing for levofloxacin
and SXT were performed by automated broth microdilution with
Vitek2. Antimicrobial sensitivities were reported and interpreted
according to the 2015 CLSI guidelines for S. maltophilia (6). Iso-
lates were then stocked and frozen at 80°C. Levofloxacin and
SXT susceptibilities for all isolates in this study were later con-
firmed by Etest (bioMérieux) at 24 h. To prepare for sequencing,
isolates were grown from single colonies in tryptic soy broth, and
DNA extraction was performed as previously described (7).
Sequencing was performed on the PacBio RSII platform (Pa-
cific Biosciences, Menlo Park, CA), and reads were assembled de
novo using PacBio’s Hierarchical Genome Assembly Process (ver-
sion 3) (8). Pairwise comparison and variant calling were per-
formed with MUMmer 3.23 (9). Mugsy 2.2 (10) was used to align
whole-genome sequences for phylogenetic reconstruction with
RAxML-8.0.2 (11), and rearrangements were visualized with
Mauve 2.4.0 (12). Additional details, including Sanger validation
methods and sequence accession numbers, are in the supplemen-
tal methods.
Two complete whole-genome sequences were derived from
patient 1’s isolates before and after the change in levofloxacin MIC
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and compared to whole-genome sequences of five control S.
maltophilia isolates (patients 2 to 6). All sequences were de novo
assembled, i.e., without regard to reference assemblies. Table 1
summarizes the relative dates of collection, antimicrobial suscep-
tibility results, and assembly statistics.
Assembled genome sequences for patient 1’s isolates before
(ISMMS2) and after (ISMMS2R) observation of levofloxacin re-
sistance were compared directly and were identical except for one
single-nucleotide variant (SNV) and five one-base indels. Sanger
sequencing confirmed the presence of the SNV but identified the
indels as homopolymer assembly errors. Coding domain se-
quence predictions for the surrounding locus (Fig. 1A) revealed
that the SNV was inside smeT, a tetR-like repressor upstream of
the structural operon for the smeDEF genes, which encode a mul-
tidrug efflux pump. The SNV is a T-to-A substitution at position
497 of smeT causing a nonsynonymous Leu-166¡Gln mutation.
The same nonsynonymous mutation has been previously ob-
served in an in vitro strain of S. maltophilia, D457R, created by
selecting single-step tetracycline-resistant mutants from the anti-
biotic-susceptible clinical strain D457 (3, 4). The mutation is in
the eighth -helix of the smeT protein (13), which ho-
modimerizes to repress transcription of the smeDEF operon (3,
13). Although the mutation is not in the DNA-binding region,
it has been shown to disable the repressor activity of SmeT (3),
leading to upregulation of smeDEF and conferring a multidrug
resistance (MDR) phenotype (14).
Figure 1B shows an amino acid sequence alignment comparing
smeT in D457 and D457R to aligned sequences from our seven
isolates. Notably, while none of the remaining isolates shared the
same Leu-166¡Gln (c.497TA) mutation, another isolate resis-
tant to levofloxacin, ISMMS4, displayed a C-to-T mutation at
position 388 of smeT, which creates a premature stop codon that
likely disrupts smeT function (Fig. 1A and B).
The QRDRs are loci within genes encoding topoisomerase II
and IV subunits known for mutations that confer quinolone re-
sistance in Gram-negative bacteria, although they appear to play a
secondary role to efflux systems for resistance emerging during
treatment of S. maltophilia infection (5). An amino acid sequence
alignment of the gyrA, gyrB, and parC genes of our seven isolates
and the reference clinical isolates D457 and K279a revealed no
differences in the QRDR. Some variants were observed within the
QRDR of parE (see Fig. S1 in the supplemental material), all of
which were consistent with past observations in clinical isolates
(15) except for an Ile-599¡Val variant observed in three of our
isolates and the D457 reference sequence.
Significant genomic diversity was observed among the S.
maltophilia isolates from all six patients. Figure S2 in the supple-
mental material shows a maximum-likelihood phylogeny with
branch lengths scaled to SNV distances. Our isolates are distrib-
uted widely among all four reference assemblies for complete S.
maltophilia genomes in GenBank. The distances of tens of thou-
sands of SNVs seen in our phylogeny suggest that the natural
diversity of pathogenic S. maltophilia is greater than that captured
by the current set of reference assemblies, even within a single
hospital setting.
Recombination is not an obvious source of diversity in our S.
maltophilia isolates. Figure S3 in the supplemental material de-
picts whole-genome alignments between the four clinical isolates
where assembly produced a circularized chromosome and the
four GenBank references, showing small areas of nonhomology
separating large regions of significant homology occurring gener-
ally in the same order for each genome. ISMMS2 and ISMMS2R
are structurally identical, as expected for serial isolates, while re-
combination events among other strains are limited to small, 1- to
2-kb, segments. Epigenetics motif analysis also suggests that the
isolates are not related. Table S1 in the supplemental material
shows different motifs in isolates from separate patients, implicat-
ing differences in type II and III restriction modification systems
between the isolates more likely to be caused by interstrain or
interspecies horizontal transfer of methyltransferases than by in-
trastrain mutations (16). Together, these observations demon-
strate that transmission did not occur among these six cases and
that whole-genome sequencing can comprehensively capture ge-
netic distances and structural variants among diverse clinical iso-
lates of S. maltophilia.
This is the first report of WGS on serial isolates to characterize
the emergence of a resistance mutation in S. maltophilia during
antibiotic treatment of an active infection. In contrast to studies
sequencing highly resistant strains of S. maltophilia to reveal var-
ious intrinsic and acquired antibiotic resistance genes (17, 18),
where it remains difficult to assess their relative importance to the
phenotype, performing WGS on serial isolates as resistance
emerges in vivo allows the causative mutation(s) to be captured. In
our patient, the mutation was a SNV that replicates a variant ob-
TABLE 1 Sequenced clinical isolates and their antimicrobial susceptibilitiesa
Patient
Time of
collectionb (days)
Isolate
name
Susceptibility (MIC [mg/liter])
Assembly quality
Depth of
coverage
Levo SXT
Vitek2 Etest Vitek2 Etest
1 0 ISMMS2 S (0.5)c S (1) S (20) S (0.19) 1 circular 4.51-Mbp chromosome 160
1 10 ISMMS2R R (32)c R (16) S (1) S (0.38) 1 circular 4.51-Mbp chromosome 403
2 26 ISMMS3 S (0.25) S (0.38) U (80,20)d S (0.75) 1 circular 4.80-Mbp chromosome 153
3 14 ISMMS4 R (8) R (12) U (0.5, 80)d S (0.75) 3 contigs (4.73 Mbp, 6.5 kbp, 11.2 kbp) 303
4 32 ISMMS5 S (1) S (1) S (20) S (0.25) 18 contigs 270
5 0 ISMMS6 S (0.12) S (0.125) S (20) S (1.5) 10 contigs 262
6 2 ISMMS7 S (1) S (0.75) S (20) S (1.5) 1 circular 4.69-Mbp chromosome,
1 additional 17.7-kbp contig
318
a Levo, levofloxacin; SXT, trimethoprim-sulfamethoxazole; S, susceptible; R, resistant; U, undetermined; Mbp, million base pairs; kbp, thousand base pairs.
b Time of collection was defined in days relative to the date of collecting the initial S. maltophilia isolate in the case patient.
c Change in levofloxacin susceptibility investigated in this study.
d Inconsistent results were obtained in replicate.
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served in an in vitro model strain created to study the MDR phe-
notype in 1997 (4). Using WGS and susceptibility testing, we can
confirm that this SNV was the only variant to emerge and that it
was sufficient to confer quinolone resistance in a clinical case. This
underscores the need for clinicians to consider repeating DST
during monotherapy if clinical signs suggest therapy failure.
smeT appears to play a central role in adaptive resistance to
quinolones and other antibiotics effluxed by smeDEF, like tetra-
cycline, chloramphenicol, erythromycin, and aminoglycosides.
Since any mutation that inactivates this protein would be able to
derepress smeDEF and confer resistance, smeT is under intense
selective pressure in the presence of these drugs. In this study, we
observed not only a deleterious SNV in the strain that displayed
resistance (ISMMS2R) but also a premature stop codon in smeT in
a strain that was already resistant at first isolation (ISMMS4). Cer-
tain nucleotide positions appear to be under greater selective pres-
sure than others, as evidenced by our observation of the same
mutation that occurred in D457R and a relative paucity of non-
synonymous coding mutations in smeT observed among clinical
smeT isolates (19). Since sustained overexpression of smeDEF is
physiologically unfavorable (20), it is possible that pathogenic
strains of S. maltophilia rely on natural diversity of mutations in
the smeT locus to activate or deactivate smeDEF expression, allow-
ing for rapid adaptation to antibiotic stress, though further study
is needed.
Since resistance from a single SNV emerged during a short
course of ciprofloxacin, clinicians should be cautioned about
using quinolone monotherapy for S. maltophilia bacteremia, as
highlighted in recent retrospective studies (21, 22). The wide
variety of MDR phenotypes and unreliability of DST results
have created uncertainty about appropriate treatment for S.
maltophilia, but SXT remains the most common choice for mono-
therapy (1, 21, 22). SXT resistance in S. maltophilia is not known
to be caused by efflux systems but has been linked to class 1
integrons and ISCR elements (1). This suggests that spontane-
ous resistance is less likely to emerge with SXT monotherapy,
although a clinical trial comparing the two antibiotics is war-
ranted (21, 22).
In conclusion, characterizing the full extent of genetic altera-
tions that S. maltophilia utilizes to develop antibiotic resistance in
vivo and improving genomic surveillance of clinical strains will
help refine antibiotic selection criteria available to clinicians. Fur-
thermore, this study highlights the utility of WGS for profiling the
precise mutations underlying emerging antibiotic resistance in
clinical cases of bacteremia.
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FIG 1 Single-nucleotide variants (SNVs) observed in quinolone-resistant S. maltophilia clinical isolates. (A) Assembled circular chromosome for ISMMS2,
including predicted coding domain sequence (CDS) and noncoding RNA (ncRNA) features drawn with ChromoZoom (23). Horizontal position corresponds
to base pair location. The smeDEF operon is shown in the detail callout, which highlights both the smeT c.497TA SNV that emerged in ISMMS2R and the
aligned location of the smeT c.388CT SNV (resulting in a premature stop codon) in ISMMS4. ISMMS2 and ISMMS2R are serial isolates from a single patient
before and after development of quinolone resistance, while ISMMS4 was quinolone resistant at initial isolation from a different patient. (B) Multiple-sequence
alignment of part of the predicted smeT product in each of the clinical isolates, the D457 reference assembly, and its quinolone-resistant counterpart D457R.
Predicted -helices (13) are depicted as gray bars below the sequence. Positions identical in all sequences are shaded with a dark gray background, equivalent
substitutions are in red, and nonequivalent substitutions are in black and boldface. The L166Q and Q130* (*, stop codon) polymorphisms are highlighted.
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Nucleotide sequence accession numbers. Complete genome
sequences for ISMMS2, ISMMS2R, and ISMMS3 were depos-
ited in GenBank under accession numbers CP011305, CP011306,
and CP011010, respectively. Deposited sequences for ISMMS2
and ISMMS2R incorporate the Sanger corrected regions de-
scribed above. Sequences for ISMMS4, ISMMS5, ISMMS6, and
ISMMS7 were deposited as whole-genome shotgun projects at
DDBJ/EMBL/GenBank under accession numbers JZIU00000000,
JZIV00000000, JZIW00000000, and JZTX00000000, respectively,
with the versions described in this paper at JZIU01000000,
JZIV01000000, JZIW01000000, and JZTX01000000, respectively.
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